2014
DOI: 10.1016/j.ajem.2014.05.030
|View full text |Cite
|
Sign up to set email alerts
|

High-dose vitamin C as treatment of methemoglobinemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
18
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(18 citation statements)
references
References 20 publications
0
18
0
Order By: Relevance
“…One notable concern for this treatment is that high doses increase urinary excretion of oxalate, which has been reported to cause oxalate nephropathy in patients with renal impairment. 9 …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…One notable concern for this treatment is that high doses increase urinary excretion of oxalate, which has been reported to cause oxalate nephropathy in patients with renal impairment. 9 …”
Section: Discussionmentioning
confidence: 99%
“…Additionally, ascorbic acid requires multiple doses much more frequently. 9 , 10 Finally, in severe cases of methemoglobinemia, exchange transfusion and hyperbaric oxygen can also be used as adjunctive or monotherapy. 11 , 12 …”
Section: Discussionmentioning
confidence: 99%
“…Vitamin C (ascorbic acid) has also been reported as a potential treatment for methemoglobinemia. 6,9 It is postulated that the antioxidant potential of vitamin C aids in reduction of heme to its ferrous state. 6,9 Current evidence for effective use of vitamin C is lacking and, if available, methylene blue should be first-line therapy.…”
Section: Discussionmentioning
confidence: 99%
“…6,9 Current evidence for effective use of vitamin C is lacking and, if available, methylene blue should be first-line therapy. 3,9…”
Section: Discussionmentioning
confidence: 99%
“…Ascorbic acid, better known as vitamin C, is one alternative due to its antioxidant effects. 22 Other investigatory therapies include N-acetylcysteine 23 and cytochrome P-450 inhibitors in dapsoneinduced methemoglobinemia, 24 although studies remain limited. Treating the underlying cause behind the production of methemoglobin, such as the oxidative stress in G6PD deficiency, can also be a form of treatment.…”
Section: Discussionmentioning
confidence: 99%